Patients with prostate cancer are less likely to develop oesophageal adenocarcinoma: could androgens have a role in the aetiology of oesophageal adenocarcinoma?

被引:22
|
作者
Cooper, Sheldon C. [1 ]
Croft, Stacey [2 ]
Day, Rosie [2 ]
Thomson, Catherine S. [2 ,3 ]
Trudgill, Nigel J. [1 ]
机构
[1] Sandwell Gen Hosp, Dept Gastroenterol, W Bromwich B71 4HJ, W Midlands, England
[2] Univ Birmingham, W Midlands Canc Intelligence Unit, Birmingham B15 2TT, W Midlands, England
[3] Canc Res UK, London WC2A 3PX, England
关键词
Oesophageal adenocarcinoma; Oesophageal cancer; Prostate cancer; Androgens; SQUAMOUS-CELL CARCINOMA; GASTRIC CARDIA; RECEPTOR EXPRESSION; BARRETTS-ESOPHAGUS; GROWTH-FACTOR; RISK-FACTORS; BODY-MASS; OBESITY; EPIDEMIOLOGY; ASSOCIATION;
D O I
10.1007/s10552-009-9359-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oesophageal adenocarcinoma (OAC) is more common in men. Androgens may therefore contribute to the pathogenesis of OAC. Prostate cancer (PC), an androgen sensitive tumor with a long natural history, may allow insights into this putative association. West Midlands Cancer Intelligence Unit data from 1977 to 2004 were examined to identify patients with a first malignant primary of PC. Patients were followed until diagnosis of a second primary cancer, death or end of the time period. Age-and period-adjusted standardized incidence ratios (SIR) were calculated as an estimate of the relative risk of a second malignant primary of the oesophagus. Between 1977 and 2004, 44,819 men within the West Midlands developed PC as a first primary malignancy. After exclusion for lack of follow-up, 38,627 men were eligible, providing 143,526 person years at risk for analysis. 86 second primary oesophageal cancers were observed, compared with 110 expected, resulting in an SIR of 0.78 (95% CI 0.62-0.96). There was a reduced risk of OAC 0.7 (0.5-0.95) but not of oesophageal squamous cell carcinoma (OSCC) 1.03 (0.69-1.47). The risk of developing OAC, but not OSCC, is lower than expected in patients with PC. A diagnosis of PC may be associated with aetiological factors that are negatively associated with OAC, or antiandrogen therapy may influence the development of OAC.
引用
收藏
页码:1363 / 1368
页数:6
相关论文
共 8 条
  • [1] Patients with prostate cancer are less likely to develop oesophageal adenocarcinoma: could androgens have a role in the aetiology of oesophageal adenocarcinoma?
    Sheldon C. Cooper
    Stacey Croft
    Rosie Day
    Catherine S. Thomson
    Nigel J. Trudgill
    Cancer Causes & Control, 2009, 20 : 1363 - 1368
  • [2] Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden
    E Chandanos
    M Lindblad
    C Jia
    C A Rubio
    W Ye
    J Lagergren
    British Journal of Cancer, 2006, 95 : 118 - 122
  • [3] Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden
    Chandanos, E.
    Lindblad, M.
    Jia, C.
    Rubio, C. A.
    Ye, W.
    Lagergren, J.
    BRITISH JOURNAL OF CANCER, 2006, 95 (01) : 118 - 122
  • [4] Adipose tissue from oesophageal adenocarcinoma patients is differentially affected by chemotherapy and chemoradiotherapy regimens altering immune cell phenotype and cancer cell metabolism
    O'Connell, Fiona
    Mylod, Eimear
    Donlon, Noel E.
    Davern, Maria
    Butler, Christine
    O'Connor, Niamh
    Menon, Meghana S.
    Donohoe, Claire L.
    Ravi, Narayanasamy
    Doherty, Derek G.
    Dunne, Margaret R.
    Reynolds, John, V
    Roche, Helen M.
    O'Sullivan, Jacintha
    TRANSLATIONAL ONCOLOGY, 2025, 53
  • [5] A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie
    Volker Kaechele
    Markus Moehler
    Manfred P. Lutz
    Goetz von Wichert
    Miriam Eisele
    Jochen Klaus
    Peter R. Galle
    Guido Adler
    Thomas Seufferlein
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 191 - 195
  • [6] A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie
    Kaechele, Volker
    Moehler, Markus
    Lutz, Manfred P.
    von Wichert, Goetz
    Eisele, Miriam
    Klaus, Jochen
    Galle, Peter R.
    Adler, Guido
    Seufferlein, Thomas
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 191 - 195
  • [7] GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level
    Schroeder, Julia
    Chegwidden, Laura
    Maj, Carlo
    Gehlen, Jan
    Speller, Jan
    Boehmer, Anne C.
    Borisov, Oleg
    Hess, Timo
    Kreuser, Nicole
    Venerito, Marino
    Alakus, Hakan
    May, Andrea
    Gerges, Christian
    Schmidt, Thomas
    Thieme, Rene
    Heider, Dominik
    Hillmer, Axel M.
    Reingruber, Julian
    Lyros, Orestis
    Dietrich, Arne
    Hoffmeister, Albrecht
    Mehdorn, Matthias
    Lordick, Florian
    Stocker, Gertraud
    Hohaus, Michael
    Reim, Daniel
    Kandler, Jennis
    Mueller, Michaela
    Ebigbo, Alanna
    Fuchs, Claudia
    Bruns, Christiane J.
    Holscher, Arnulf H.
    Lang, Hauke
    Grimminger, Peter P.
    Dakkak, Dani
    Vashist, Yogesh
    May, Sandra
    Gorg, Siegfried
    Franke, Andre
    Ellinghaus, David
    Galavotti, Sara
    Veits, Lothar
    Weismuller, Josef
    Dommermuth, Jens
    Benner, Udo
    Roesch, Thomas
    Messmann, Helmut
    Schumacher, Brigitte
    Neuhaus, Horst
    Schmidt, Carsten
    GUT, 2023, 72 (04) : 612 - 623
  • [8] The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: A rare cancer network retrospective study
    Nguyen, TD
    Poortmans, PMP
    van der Hulst, M
    Studer, G
    Pigois, E
    Collen, TD
    Belkacemi, Y
    Beckendorf, W
    Miralbell, R
    Scandolaro, L
    Soete, G
    Villa, S
    Gez, E
    Thomas, O
    Krengli, M
    Jovenin, N
    RADIOTHERAPY AND ONCOLOGY, 2005, 77 (03) : 286 - 289